CANY
PACB icon

Caxton Associates (New York)’s Pacific Biosciences PACB Stock Holding History

Caxton Associates (New York)’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$577K Buy
+315,348
New +$616K 0.02% 306

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caxton Associates (New York)'s PACB Position: Q4 2024 in Review

Caxton Associates (New York) opened a new position in Pacific Biosciences (PACB) in Q4 2024: 315,348 shares worth $577K. The stake represents 0.02% of the portfolio and ranks #306 among its holdings.

226 funds tracked by Wall St. Rank hold PACB as of Q4 2024.

  • Caxton Associates (New York) held 315,348 shares of Pacific Biosciences worth $577K as of Q4 2024.
  • Pacific Biosciences was a new Caxton Associates (New York) position in Q4 2024.
  • Pacific Biosciences made up 0.02% of Caxton Associates (New York)'s portfolio in Q4 2024, its #306 holding.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.